文献速递食管与纵隔外科

食管切除术延迟的患者、机构及手术因素与不良结局:16,486例分析

Patient, facility, and surgical factors associated with significant delays to esophagectomy and subsequent poor outcomes: An analysis of 16,486 cases.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-11-07

基于美国国家癌症数据库2010-2020年局部晚期食管腺癌(I-III期)患者,分析至食管切除术时间的预测因素及其对肿瘤和生存结局的影响。共纳入16,486例,分为直接手术组和新辅助放化疗后手术组,发现缺乏保险、低教育水平、活检分期或手术分期、机器人辅助入路等与延迟相关,延迟与病理升期或90天死亡率增加相关。

要点

  • 直接手术组中位至手术时间61天,延迟阈值为96天。
  • 新辅助放化疗组中位至手术时间55天,延迟阈值为56天。
  • 直接手术组延迟与病理升期风险增加相关(OR 1.31)。

核心结论

  • 风险调整后,患者、肿瘤、机构和手术特征中存在多个与食管切除术时间延长相关的预测因素,且延迟与病理升期和生存不良相关。

研究设计与样本

  • 回顾性队列研究,查询美国国家癌症数据库2010至2020年局部晚期食管腺癌(I-III期)患者16,486例。
  • 患者分为直接手术组(4,066例,24.7%)和新辅助放化疗后手术组(12,420例,75.3%)。

主要发现

  • 直接手术组中位至手术时间61天(IQR 40-96天),新辅助放化疗组55天(IQR 44-70天)。
  • 直接手术组延迟的预测因素包括缺乏保险、最低教育四分位、活检分期或手术分期、机器人辅助入路。
  • 新辅助放化疗组延迟的预测因素包括西班牙裔、医疗补助或其他政府保险、最低教育四分位、机器人入路。
  • 直接手术组延迟与病理升期风险增加相关(OR 1.31,95%CI 1.06-1.61)。
  • 新辅助放化疗组延迟与90天死亡率增加相关(OR 1.27,95%CI 1.06-1.51)。

关键数值与推荐

  • 直接手术组延迟定义为至手术时间超过96天,新辅助放化疗组超过56天。

临床怎么用

  • 对缺乏保险、低教育水平、机器人辅助入路等患者应关注手术延迟风险,优化流程以减少延迟。
  • 直接手术患者应尽量避免延迟以降低病理升期风险,新辅助放化疗后患者应避免延迟以降低90天死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Delays to definitive surgery in esophageal cancer may be associated with disease progression and worsened survival. The objective of this study was to perform a national assessment for predictors of delay to esophagectomy and to assess for their impact on oncologic and survival outcomes. METHODS: The National Cancer Database, 2010 to 2020, was queried for patients with locally advanced esophageal adenocarcinoma (stage I-III). Patients were divided into up-front and postneoadjuvant chemoradiation cohorts. The primary outcome was time to surgery. Time to surgery was examined as a continuous and categorical variable, where patients were divided into timely and delayed cohorts (96 days for up-front cohort; 56 days for postneoadjuvant chemoradiation cohort). RESULTS: Of 16,486 patients, 4066 (24.7%) underwent up-front surgery and 12,420 (75.3%) underwent postneoadjuvant chemoradiation surgery. In the up-front surgery group, median [interquartile range] time to surgery was 61 [40-96] days. Risk-adjusted predictors of delay included lack of insurance, lowest quartile of education, biopsy-based staging or surgical staging, and robotic-assisted approach. In the postneoadjuvant chemoradiation, cohort time to surgery was 55 [44-70] days. Risk-adjusted predictors of delay included Hispanic ethnicity, Medicaid or other government-based insurance, lowest quartile of educational status, and robotic approach. In the up-front surgery group, patients who received delayed surgery had increased odds of pathologic upstaging (1.31, 95% CI, 1.06-1.61). In the postneoadjuvant chemoradiation group, patients with surgical delay had increased odds of 90-day mortality (1.27, 95% CI, 1.06-1.51). CONCLUSIONS: After risk adjustment for patient, oncologic, facility, and surgical characteristics, there were several predictors of increased time to esophagectomy associated with consequences of upstaging and survival.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Stuart CM, Dyas AR, Yee EJ, et al. Patient, facility, and surgical factors associated with significant delays to esophagectomy and subsequent poor outcomes: An analysis of 16,486 cases. J Thorac Cardiovasc Surg. 2024. PMID: 39515604. doi:10.1016/j.jtcvs.2024.10.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。